BACKGROUND: Only 10-25% of patients presenting with colorectal liver metastases (CRLM) are amenable to hepatic resection. By combining resection and ablation, the number of patients eligible for surgery can be expanded. We sought to determine the efficacy of combined resection and ablation for CRLM. METHODS: Between 1984 and 2009, 1,425 patients who underwent surgery for CRLM were queried from an international multi-institutional database. Of these, 125 patients underwent resection combined with ablation as the primary mode of treatment. RESULTS: Patients presented with a median of six lesions. The median number of lesions resected was 4; the median number of lesions ablated was 1. At last follow-up, 84 patients (67%) recurred with a median disease-free interval of 15 months. While total number of lesions treated (hazard ratio (HR) = 1.47, p = 0.23) and number of lesions resected (HR = 1.18, p = 0.43) did not impact risk of intrahepatic recurrence, the number of lesions ablated did (HR = 1.36, p = 0.05). Overall 5-year survival was 30%. Survival was not influenced by the number of lesions resected or ablated (both p > 0.05). CONCLUSION: Combined resection and ablation is associated with long-term-survival in a subset of patients; however, recurrence is common. The number of lesions ablated increases risk of intrahepatic recurrence but does not impact overall survival.
BACKGROUND: Only 10-25% of patients presenting with colorectal liver metastases (CRLM) are amenable to hepatic resection. By combining resection and ablation, the number of patients eligible for surgery can be expanded. We sought to determine the efficacy of combined resection and ablation for CRLM. METHODS: Between 1984 and 2009, 1,425 patients who underwent surgery for CRLM were queried from an international multi-institutional database. Of these, 125 patients underwent resection combined with ablation as the primary mode of treatment. RESULTS:Patients presented with a median of six lesions. The median number of lesions resected was 4; the median number of lesions ablated was 1. At last follow-up, 84 patients (67%) recurred with a median disease-free interval of 15 months. While total number of lesions treated (hazard ratio (HR) = 1.47, p = 0.23) and number of lesions resected (HR = 1.18, p = 0.43) did not impact risk of intrahepatic recurrence, the number of lesions ablated did (HR = 1.36, p = 0.05). Overall 5-year survival was 30%. Survival was not influenced by the number of lesions resected or ablated (both p > 0.05). CONCLUSION: Combined resection and ablation is associated with long-term-survival in a subset of patients; however, recurrence is common. The number of lesions ablated increases risk of intrahepatic recurrence but does not impact overall survival.
Authors: Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: D A Wicherts; R J de Haas; P Andreani; D Sotirov; C Salloum; D Castaing; R Adam; D Azoulay Journal: Br J Surg Date: 2010-02 Impact factor: 6.939
Authors: Fredericke H van Duijnhoven; Maarten C Jansen; Jan M C Junggeburt; Richard van Hillegersberg; Arjen M Rijken; Frits van Coevorden; Joost R van der Sijp; Thomas M van Gulik; Gerrit D Slooter; Joost M Klaase; Hein Putter; Rob A E M Tollenaar Journal: Ann Surg Oncol Date: 2006-03-17 Impact factor: 5.344
Authors: Bram Fioole; Maarten C Jansen; Frederieke H van Duijnhoven; Richard van Hillegersberg; Thomas M van Gulik; Inne Hm Borel Rinkes Journal: World J Surg Oncol Date: 2006-07-17 Impact factor: 2.754
Authors: C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi Journal: Curr Oncol Date: 2018-08-14 Impact factor: 3.677
Authors: Eddie K Abdalla; Todd W Bauer; Yun S Chun; Michael D'Angelica; David A Kooby; William R Jarnagin Journal: HPB (Oxford) Date: 2013-02 Impact factor: 3.647
Authors: Skye C Mayo; Jennifer E Heckman; Andrew D Shore; Hari Nathan; Alexander A Parikh; John F P Bridges; Robert A Anders; Daniel A Anaya; Natasha S Becker; Timothy M Pawlik Journal: Surgery Date: 2011-08 Impact factor: 3.982
Authors: Skye C Mayo; Andrew D Shore; Hari Nathan; Barish H Edil; Kenzo Hirose; Robert A Anders; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: HPB (Oxford) Date: 2011-05-18 Impact factor: 3.647
Authors: Peter D Peng; Mark G van Vledder; Susan Tsai; Mechteld C de Jong; Martin Makary; Julie Ng; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Ihab Kamel; Timothy M Pawlik Journal: HPB (Oxford) Date: 2011-03-29 Impact factor: 3.647
Authors: Omar Hyder; Carlo Pulitano; Amin Firoozmand; Rebecca Dodson; Christopher L Wolfgang; Michael A Choti; Luca Aldrighetti; Timothy M Pawlik Journal: J Am Coll Surg Date: 2013-03-09 Impact factor: 6.113
Authors: Alison L Halpern; J Gregory Fitz; Yuki Fujiwara; Jeniann Yi; Aimee L Anderson; Yuwen Zhu; Richard D Schulick; Karim C El Kasmi; Carlton C Barnett Journal: Am J Physiol Cell Physiol Date: 2020-11-11 Impact factor: 4.249